Gilead Sciences, Inc. operates in the Biological products exc. diagnostic sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Gilead Sciences with three other
pharmaceutical manufacturers in North America:
Eli Lilly and Company
sales of $22.87 billion
of which 44%
was Human pharmaceutical products - Endocrin),
of which 33%
was Vascular Products), and
of which 100%
was Pharmaceutical Products).
Gilead Sciences reported sales of $26.11 billion
December of 2017.
decrease of 14.1%
versus 2016, when the company's sales were $30.39 billion.
Contributing to the drop in overall sales was the 15.9% decline
in Antiviral Products, from $27.75 billion to $23.34 billion.
However, these declines were partially offset by the increase in sales of
Other Products (up 5.3% to $2.33 billion)